Free tool
FAERS Monitor: Luzu
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204153 or its brand name (Luzu, Luliconazole). Reports on generic versions are filed under their own applications.
Reports
176
Serious
131
74% of reports
Hospitalization
84
Death reported
15
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective12
- hepatic function abnormal9
- nausea9
- constipation8
- pyrexia8
- decreased appetite7
- off label use7
- diarrhoea6
- pneumonia6
- anaemia5
- anxiety5
- erythema5
- sleep disorder5
- acute kidney injury4
- alanine aminotransferase increased4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2010 | 2 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 6 |
| 2015 | 10 |
| 2016 | 26 |
| 2017 | 6 |
| 2018 | 13 |
| 2019 | 12 |
| 2020 | 4 |
| 2021 | 11 |
| 2022 | 21 |
| 2023 | 14 |
| 2024 | 15 |
| 2025 | 18 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,983 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatic function abnormalSignal | 9 | 28.8 | 15.3 | 215 |
| sleep disorderSignal | 5 | 8.5 | 3.6 | 26 |
| alanine aminotransferase increasedSignal | 4 | 7.8 | 3.0 | 17 |
| constipationSignal | 8 | 4.4 | 2.2 | 18 |
| decreased appetiteSignal | 7 | 3.6 | 1.7 | 11 |
| anaemiaSignal | 5 | 3.1 | 1.3 | 5 |
| acute kidney injury | 4 | 3.1 | 1.2 | 4 |
| erythemaSignal | 5 | 2.9 | 1.2 | 5 |
| pyrexiaSignal | 8 | 2.8 | 1.4 | 7 |
| pneumonia | 6 | 2.2 | 1.0 | 3 |
| anxiety | 5 | 2.1 | 0.9 | 2 |
| nausea | 9 | 1.4 | 0.7 | 1 |
| diarrhoea | 6 | 1.1 | 0.5 | 0 |
| drug ineffective | 12 | 1.1 | 0.6 | 0 |
| off label use | 7 | 1.0 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.